

# BC Cancer Protocol Summary of Yttrium-90 for Transarterial Radioembolisation (TARE) for Locally Advanced Cholangiocarcinoma or Gallbladder Carcinoma Not Amenable for Surgical Resection

**Protocol Code**

*GIBYTT*

**Tumour Group**

*Gastrointestinal*

**Contact Physician**

*Dr. Dave Liu*

*Dr. Theresa Chan*

## **ELIGIBILITY:**

Suitability for Yttrium-90 TARE therapy will be established via consultation with Intervention Radiology at accredited sites (institutions that have completed and maintained the proctoring or qualification for administration of Y-90), in accordance with the following eligibility criteria:

- Locally advanced cholangiocarcinoma or gallbladder carcinoma not amenable for surgical resection at time of presentation

Note: patients would be reviewed in Multi-Disciplinary Rounds and considered for local regional options such as SBRT or radioembolization

All patients should have:

- Definable disease burden by imaging criteria
- Mesenteric vascular anatomy amenable to TARE
- Adequate liver function

## **EXCLUSIONS:**

- Infiltrative disease greater than 50% or Childs Pugh score greater than 8 (late B)
- Metastatic disease
- Life expectancy less than 3 months
- Compromised hepatic function consisting of Total Bilirubin greater than 2.5 x ULN, hypoalbuminemia less than 3.0 g/dL, AST, ALT or ALP greater than 5 x ULN

## **TREATMENT:**

### **Prescribing**

- Written directive for prescribed dose (radioactivity) from Nuclear Medicine physician in conjunction with Interventional Radiology

### **Delivery of treatment**

- Treatment must be performed in the angiography suite

**Call the GI Systemic Therapy physician at your regional cancer centre or the GI Systemic Therapy Chair Dr. Theresa Chan at (604) 877-6000 or 1-800-670-3322 with any problems or questions regarding this treatment program.**

**References:**

1. Buettner S, Braat A, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. *J Vasc Interv Radiol.* 2020;31(7):1035–1043.e2.
2. Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W. Resin-based yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. *J Cancer Res Clin Oncol.* 2017;143(3):481–489.
3. Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. *Cardiovasc Intervent Radiol.* 2012;35(1):105–116.
4. Swinburne NC, Biederman DM, Besa C, et al. Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival. *Cancer Biother Radiopharm.* 2017;32(5):161–168.